Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piamprizumab plus platinum-paclitaxel chemotherapy and anlotinib for first-line advanced cervical cancer
ChiCTR2200062897Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of piamprizumab, anlotinib, paclitaxel, cisplatin and carboplatin in Cervical Cancer (CC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
piamprizumabanlotinibpaclitaxelcisplatincarboplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2200062897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062897.